SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CVTX - CV Therapeutics, Inc.
An SI Board Since January 1999
Posts SubjectMarks Bans
411 31 0
Emcee:  Todd N. Weisrock Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
236piper: CVTX :3Q CVTX Update Creates Buying Opportunity 2005-10-26 03:25 (New Yormopgcw-10/31/2005
235piper: CVTX :Details From Phase III Regadenoson Study 2005-10-04 02:25 (New Yorkmopgcw-10/28/2005
234yep, down 10% a-hrs; alas. CV Therapeutics Reports Third Quarter 2005 Financmopgcw-10/25/2005
233[Withdraws ranolazine MAA in Europe, will resubmit with PK studies] This may hutuck-10/25/2005
232[ASCOT results] >>STOCKHOLM, Sweden, Sept. 4 /PRNewswire-FirstCall/ -- CVtuck-9/4/2005
231[PREAMI results] >>STOCKHOLM, Sweden, Sept. 4 /PRNewswire-FirstCall/ -- Ctuck-9/4/2005
230FDA Approves ACEON(R) to Reduce Risk of Cardiovascular Mortality or Non-Fatal MImopgcw-8/23/2005
229CV Therapeutics (CVTX) 9:41 AM EDT August 19, 2005 Morgan Joseph initiates BUY. mopgcw-8/22/2005
228Regadenoson Meets Primary Endpoint in First Phase 3 Trial Wednesday August 10, 4mopgcw-8/10/2005
227CV Therapeutics Reports Second Quarter 2005 Financial Results Monday August 8, 4mopgcw-8/8/2005
226Message 21518367mopgcw-7/19/2005
225CV Therapeutics Initiates Clinical Program for Potential Novel Treatment of Asthmopgcw-7/14/2005
224CV Therapeutics to Redeem 4.75% Convertible Subordinated Notes Due 2007 Wednesdamopgcw-7/13/2005
223Greedy batards: CV Therapeutics Files $55M Mixed Securities Shelf DOW JONES NEmopgcw-6/29/2005
222CV Therapeutics 7.3M-Shr Secondary Prices At $21.60/Shr DOW JONES NEWSWIRES Junmopgcw-6/29/2005
221CV Therapeutics Announces Concurrent Public Offerings of Common Stock and Convermopgcw-6/22/2005
220Risk Factor #4 comes into play today. >>PALO ALTO, Calif. (AP) -- Drug matuck-6/20/2005
219Piper: CVTX :Updating Model for 1Q Results April 27, 2005 CVTX - $19.89 Outpermopgcw-6/14/2005
218First Albany: CVTX :Reminder: FDA Deadline On Aceon Label Expansion Is Today Jumopgcw-6/14/2005
217CV Therapeutics Reports 2005 First Quarter Financial Results Tuesday April 26, 4mopgcw-4/27/2005
216CV Therapeutics Meets Ranexa Endpoint Monday April 18, 8:35 am ET CV TherapeDoc Bones-4/18/2005
215CV Therapeutics (CVTX) Needham Mark Monane Upgrade Strong buy (from buy) -2% $ 2mopgcw-4/4/2005
214ISSUER: CV THERAPEUTICS SYMBOL: CVTX FILER: SHENK THOMAS E TITLE: Director DATEmopgcw-3/18/2005
213CV Therapeutics Reports Fourth Quarter and Year End Financial Results for 2004 Tmopgcw-2/28/2005
212FDA Accepts ACEON(R) Supplemental New Drug Application for Filing Tuesday Februamopgcw-2/16/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News